Brief: Shanghai Henlius Biotech Says Unit's Hanbeiyou (Pertuzumab Injection) Passes GMP Inspection
17/06/2026 10:16
BRIEF-Shanghai Henlius Biotech Says Unit's Hanbeiyou (Pertuzumab Injection) Passes GMP Inspection June 17 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK:
HANBEIYOU (PERTUZUMAB INJECTION) PASSES GMP COMPLIANCE INSPECTION
UNIT PASSES GMP INSPECTION BY SHANGHAI MEDICAL PRODUCTS ADMINISTRATION
Further company coverage: 2696.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln